Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MB-101,MB-108
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MB-109 is Mustang’s designation for the treatment regimen combining MB-101 (COH-developed IL13Rα2‐targeted CAR-T cell therapy) with MB-108 (Nationwide-developed HSV-1 oncolytic virus), which is investigated for Recurrent Glioblastoma and High-Grade ...
Brand Name : MB-109
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 26, 2023
Lead Product(s) : MB-101,MB-108
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MB-101
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : City of Hope
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MB-101, an IL13Rα2-targeted CAR T cell therapy demonstrate durable complete responses in GBM based on a 54-patient Phase 1 trial, as an optimized CAR T product incorporating enhancements in CAR design and T cell engineering to improve antitumor potency ...
Brand Name : MB-101
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 09, 2022
Lead Product(s) : MB-101
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : City of Hope
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?